The willingness of decision makers to take risks increases when they play games of chance with money won earlier. Risk taking also rises when they have the opportunity to compensate … continue reading
Addressing the members of Consultative Committee for the Ministry of Civil Aviation in Panjim, Goa, Indian Minister of Civil Aviation, Shri Ajit Singh said that India is poised to be … continue reading
US giant Starbucks, the world’s biggest coffee chain, says an increase in customers boosted revenue in the fourth quarter by 6%. The company said net income at its shops open … continue reading
When you sit down to read a restaurant menu, do you read it like a book? Or do your eyes flit from place to place to find the most enticing dish?
A new study by SF State researcher Sybil Yang, assistant professor of hospitality and tourism management, suggests that on average diners read menus sequentially like a book, and that their gaze doesn’t linger noticeably longer over any particular location on the menu.
GlaxoSmithKline (GSK) and Synta Pharmaceuticals Corp. announced the execution of a global collaboration agreement for the joint development and commercialisation of STA-4783, a first-in-class, small-molecule, oxidative stress inducer that is entering Phase 3 clinical development for the treatment of metastatic melanoma.
Shire BioChem Inc. announced that it is pleased to support Canada?s Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture in Canada a generic fixed dose triple combination antiretroviral medicine that contains a drug (3TC?) over which Shire BioChem Inc. holds patent rights in Canada.
GlaxoSmithKline GSK announced that it has given consent to Toronto-based drug company Apotex to use two of its patented antiretroviral drugs, lamivudine and zidovudine, to manufacture Apo-triAvir — a fixed-dose combination of the two drugs and the antiretroviral nevirapine — for the treatment of HIV/AIDS in Rwanda.
On the heels of the fourth International AIDS Society?s Conference on HIV Pathogenesis, Treatment and Prevention, which took place in Sydney in late July, AIDS Healthcare Foundation (AHF) welcomed yesterday?s news that the FDA has approved Pfizer Inc.?s new AIDS salvage therapy, Selzentry (maraviroc), a different class of new antiretroviral AIDS drug which had been discussed and presented at the IAS conference.
As part of its broad commitment to improving access to medicines, GlaxoSmithKline announced it has given consent through Canada?s Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing two molecules over which GSK has patent rights (zidovudine and lamivudine) for the treatment of HIV/AIDS in Rwanda.
A new method of setting limits on what the federal government will reimburse state Medicaid agencies for prescription drug payments ? aimed at reigning in inflated drug product payments ? was announced in a final rule put on display at the Federal Register.